Yu Tao, Tang Hua-Yu, Wang Tian-Shu, Wei Wei
Second Ward of Orthopedis Department, First Affiliated Hospital of Jiamusi University, Jiamusi, China.
Medicine (Baltimore). 2019 Aug;98(32):e16783. doi: 10.1097/MD.0000000000016783.
This study aims to investigate the effectiveness and safety of electrical stimulation (ES) for postoperative pain (PPP) in patients with osteosarcoma systematically.
We will systematically search the following electronic databases from inception to the May 1, 2019: MEDILINE, Cochrane Library, EMBASE, Web of Science, Springer, and CNKI without language restrictions. All literatures of randomized controlled trials (RCTs) and case-controlled studies (CCSs) of ES for PPP in patients with osteosarcoma will be included. RevMan 5.3 software (Cochrane Community; London, UK) and STATA 15.0 software (StataCorp; College Station) will be used for statistical analysis. Cochrane risk of bias will be used for methodological quality assessment for RCTs and Newcastle-Ottawa Scale will be utilized for CCSs.
This study will assess the clinical effectiveness and safety of ES for PPP in patients with osteosarcoma through assessing primary outcome of pain intensity and secondary outcomes of frequency of rescue analgesic use, cumulative morphine consumption, quality of recovery, as well as adverse events.
This study will provide latest evidence on effectiveness and safety of ES for PPP in patients with osteosarcoma, and may also provide guidance for both clinician and further studies.
This study does not require ethical approval, because it will not analyze the individual patient data. Its results are expected to be published in peer-reviewed journals.
PROSPERO CRD42019135790.
本研究旨在系统调查电刺激(ES)对骨肉瘤患者术后疼痛(PPP)的有效性和安全性。
我们将对以下电子数据库进行系统检索,检索时间范围从建库至2019年5月1日:MEDILINE、Cochrane图书馆、EMBASE、科学引文索引、施普林格和中国知网,无语言限制。纳入所有关于骨肉瘤患者ES治疗PPP的随机对照试验(RCT)和病例对照研究(CCS)的文献。将使用RevMan 5.3软件(Cochrane协作网;英国伦敦)和STATA 15.0软件(StataCorp;美国大学城)进行统计分析。Cochrane偏倚风险评估将用于RCT的方法学质量评估,纽卡斯尔-渥太华量表将用于CCS。
本研究将通过评估疼痛强度的主要结局以及急救镇痛药物使用频率、吗啡累积消耗量、恢复质量以及不良事件等次要结局,来评估ES治疗骨肉瘤患者PPP的临床有效性和安全性。
本研究将为ES治疗骨肉瘤患者PPP的有效性和安全性提供最新证据,也可能为临床医生和进一步研究提供指导。
本研究无需伦理批准,因为它不会分析个体患者数据。其结果有望发表在同行评审期刊上。
PROSPERO CRD42019135790。